MY196909A - Boronic acid derivatives and therapeutic uses thereof - Google Patents

Boronic acid derivatives and therapeutic uses thereof

Info

Publication number
MY196909A
MY196909A MYPI2018002676A MYPI2018002676A MY196909A MY 196909 A MY196909 A MY 196909A MY PI2018002676 A MYPI2018002676 A MY PI2018002676A MY PI2018002676 A MYPI2018002676 A MY PI2018002676A MY 196909 A MY196909 A MY 196909A
Authority
MY
Malaysia
Prior art keywords
acid derivatives
boronic acid
therapeutic uses
blls
preparation
Prior art date
Application number
MYPI2018002676A
Inventor
Hecker Scott
K Reddy Raja
Glinka Tomasz
Rodny Olga
Original Assignee
Qpex Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qpex Biopharma Inc filed Critical Qpex Biopharma Inc
Publication of MY196909A publication Critical patent/MY196909A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, ?-lactamase inhibitors (BLls).
MYPI2018002676A 2016-06-30 2017-06-28 Boronic acid derivatives and therapeutic uses thereof MY196909A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662357165P 2016-06-30 2016-06-30
PCT/US2017/039787 WO2018005662A1 (en) 2016-06-30 2017-06-28 Boronic acid derivatives and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
MY196909A true MY196909A (en) 2023-05-09

Family

ID=60785544

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018002676A MY196909A (en) 2016-06-30 2017-06-28 Boronic acid derivatives and therapeutic uses thereof

Country Status (23)

Country Link
US (4) US10294249B2 (en)
EP (1) EP3478693B1 (en)
JP (1) JP7060245B2 (en)
KR (1) KR102403296B1 (en)
CN (1) CN109415386B (en)
AU (1) AU2017290060B2 (en)
BR (1) BR112018077015B1 (en)
CA (1) CA3026582A1 (en)
CL (1) CL2018003681A1 (en)
CO (1) CO2018013978A2 (en)
DK (1) DK3478693T3 (en)
ES (1) ES2894251T3 (en)
IL (1) IL263450B (en)
MX (1) MX2018015892A (en)
MY (1) MY196909A (en)
PH (1) PH12018502747A1 (en)
PL (1) PL3478693T3 (en)
PT (1) PT3478693T (en)
SA (1) SA518400742B1 (en)
SG (1) SG11201811549UA (en)
UA (1) UA124464C2 (en)
WO (1) WO2018005662A1 (en)
ZA (1) ZA201808327B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2789177T3 (en) 2010-08-10 2020-10-26 Melinta Therapeutics Inc Cyclic boronic acid ester derivatives, process for their preparation and therapeutic uses thereof
US9040504B2 (en) 2013-01-10 2015-05-26 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
JP6622721B2 (en) 2014-06-11 2019-12-18 ベナトルクス ファーマシューティカルズ，インク． Beta-lactamase inhibitor
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3347008B1 (en) 2015-09-11 2022-03-09 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR102403296B1 (en) 2016-06-30 2022-05-27 큐펙스 바이오파마 인코포레이티드 Boronic acid derivatives and therapeutic uses thereof
JOP20190188A1 (en) 2017-02-01 2019-08-01 Rempex Pharmaceuticals Inc Apparatus and continuous flow process for production of boronic acid derivative
WO2018165048A1 (en) 2017-03-06 2018-09-13 VenatoRx Pharmaceuticals, Inc. Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
MX2020003495A (en) 2017-10-11 2020-09-18 Qpex Biopharma Inc Boronic acid derivatives and synthesis thereof.
WO2019204419A1 (en) * 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
AU2019386849A1 (en) * 2018-11-29 2021-07-15 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor and uses thereof
CN114340639A (en) 2019-06-19 2022-04-12 Qpex生物制药有限公司 Boronic acid derivatives and their therapeutic use
TW202123945A (en) * 2019-09-13 2021-07-01 日商鹽野義製藥股份有限公司 Pharmaceutical composition having antibacterial activity
CA3155559A1 (en) * 2019-10-25 2021-04-29 Sachiko Koike Novel substituted condensed ring compound
IL296515A (en) * 2020-03-18 2022-11-01 Qpex Biopharma Inc Boronic acid derivatives and therapeutic uses thereof
JP2023524525A (en) * 2020-05-05 2023-06-12 キューペックス バイオファーマ， インコーポレイテッド Boronic Acid Derivatives, and Their Synthesis, Polymorphs, and Therapeutic Uses
CN116615431A (en) * 2020-08-20 2023-08-18 辉诺生物医药科技（杭州）有限公司 Boric acid compound
WO2022217199A1 (en) * 2021-04-05 2022-10-13 Qpex Biopharma, Inc. Ceftibuten dosing regimens
AU2022257156A1 (en) 2021-04-13 2023-11-16 Tuojie Biotech (Shanghai) Co., Ltd. BORIC ACID DERIVATIVE ACTING AS β-LACTAMASE INHIBITOR
CN113150022B (en) * 2021-04-23 2022-12-06 四川大学 3-substituted five-membered cyclic borate derivative, and pharmaceutical composition and pharmaceutical application thereof
WO2023066292A1 (en) * 2021-10-19 2023-04-27 上海济煜医药科技有限公司 Tricyclic boronic acid derivative, and preparation method therefor and application thereof
WO2023155869A1 (en) * 2022-02-18 2023-08-24 辉诺生物医药科技（杭州）有限公司 Crystalline form of new boric acid-based compound and preparation method therefor
CN114716465A (en) * 2022-05-06 2022-07-08 上海中医药大学 Preparation method and application of bicyclic borate compound

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3686398A (en) 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
US4260543A (en) 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
US4409214A (en) 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
US4353807A (en) 1981-03-24 1982-10-12 Mobil Oil Corporation Lubricants and fuels containing boroxarophenanthrene compounds
FR2573070B1 (en) 1984-11-13 1987-01-30 Rhone Poulenc Sante PROCESS FOR THE PREPARATION OF CARBONYL COMPOUNDS
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US4822786A (en) 1986-07-01 1989-04-18 Kaken Pharmaceutical Co., Ltd. Cephalosporin compounds, and antibacterial agents
ZA893284B (en) 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
US5442100A (en) 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
US5888998A (en) 1997-04-24 1999-03-30 Synphar Laboratories, Inc. 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
JP2002504122A (en) 1997-06-13 2002-02-05 ノースウエスタン ユニバーシティー Beta-lactamase inhibitors and methods of use
WO2000035904A1 (en) 1998-12-16 2000-06-22 Northwestern University INHIBITORS OF β-LACTAMASES AND USES THEREFOR
WO2000035905A1 (en) 1998-12-16 2000-06-22 Northwestern University INHIBITORS OF β-LACTAMASES AND USES THEREFOR
NZ517865A (en) 1999-09-25 2003-11-28 Smithkline Beecham P Piperazine derivatives as 5-HT1B antagonists
CA2388077A1 (en) 1999-10-28 2001-05-03 James M. Balkovec Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections
AU2001292732A1 (en) 2000-09-12 2002-03-26 Larry C. Blasczcak Beta-lactam analogs and uses therefor
BR0113861A (en) 2000-09-14 2004-01-27 Pantherix Ltd 3- (Heteroaryl acetamido) -2-oxo-azetidine-1-sulfonic acid derivatives as antibacterial agents
US6586615B1 (en) 2001-01-10 2003-07-01 Bristol-Myers Squibb Company α-aminoboronic acids prepared by novel synthetic methods
DE10118698A1 (en) 2001-04-17 2002-11-07 Jerini Ag Immobilization method and arrangement of connections produced therewith on a planar surface
AU2002360732A1 (en) * 2001-12-26 2003-07-24 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
FR2835186B1 (en) 2002-01-28 2006-10-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS
JP2003229277A (en) 2002-02-04 2003-08-15 Matsushita Electric Ind Co Ltd Material for light emitting element, light emitting element and light emitting device using the same
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
CN100528846C (en) 2002-09-11 2009-08-19 株式会社吴羽 Amine compounds and use thereof
EP1571170B1 (en) 2002-10-30 2018-09-05 Sumitomo Chemical Company, Limited High-molecular compounds and polymer light emitting devices made by using the same
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
JP2006511587A (en) 2002-12-20 2006-04-06 ミジェニックス コーポレイション Adenine nucleotide translocase (ANT) ligand and related compositions and methods
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
JP4233365B2 (en) 2003-03-25 2009-03-04 三井化学株式会社 Azadiol complex compound and optical recording medium using the compound
WO2005033090A1 (en) 2003-10-06 2005-04-14 Sumitomo Chemical Company, Limited Aromatic compound
CA2541832C (en) 2003-10-10 2009-11-24 Pfizer Products Inc. Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors
EP1689757B1 (en) * 2003-11-12 2014-08-27 Phenomix Corporation Heterocyclic boronic acid compounds
TW200600494A (en) 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
US20060019116A1 (en) 2004-07-22 2006-01-26 Eastman Kodak Company White electroluminescent device with anthracene derivative host
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US20060178357A1 (en) 2005-02-10 2006-08-10 Buynak John D Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases
ES2414095T3 (en) 2005-02-16 2013-07-18 Anacor Pharmaceuticals, Inc. Halogen-substituted boronoptalides for the treatment of infections
WO2006091770A2 (en) 2005-02-22 2006-08-31 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
WO2006101779A2 (en) 2005-03-15 2006-09-28 The University Of Chicago Non-aqueous electrolytes for lithium ion batteries
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
EP2484680B1 (en) 2005-12-07 2013-06-26 Basilea Pharmaceutica AG Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors
PL2719388T3 (en) 2006-02-16 2019-11-29 Anacor Pharmaceuticals Inc Boron-containing small molecules as anti-inflammatory agents
AU2007300531A1 (en) 2006-09-27 2008-04-03 Merck Sharp & Dohme Corp. Novel inhibitors of beta-lactamase
CA2680018C (en) 2007-03-23 2014-01-07 Basilea Pharmaceutica Ag Combination medicaments for treating bacterial infections
PT2181103E (en) * 2007-07-23 2015-11-18 Univ Illinois System for controlling the reactivity of boronic acids
CN101939053A (en) * 2007-09-06 2011-01-05 默沙东公司 Soluble guanylate cyclase activators
GB0719366D0 (en) 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
AR069310A1 (en) 2007-11-13 2010-01-13 Protez Pharmaceuticals Inc BETA-LACTAMASA INHIBITORS
SI2231667T1 (en) 2008-01-18 2013-12-31 Merck Sharp & Dohme Corp. Beta-lactamase inhibitors
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
EP2285384A4 (en) 2008-05-12 2012-04-25 Anacor Pharmaceuticals Inc Boron-containing small molecules
CN102098918A (en) 2008-05-13 2011-06-15 帕纳德制药公司 Bioactive compounds for treatment of cancer and neurodegenerative diseases
WO2010075286A1 (en) 2008-12-24 2010-07-01 University Of Washington MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY
WO2010097675A1 (en) 2009-02-27 2010-09-02 Dhanuka Laboratories Ltd. An improved preparation process for cefpodoxime proxetil
EP2406233B1 (en) * 2009-03-09 2013-11-13 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
US20100292185A1 (en) 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
CN105175409A (en) 2009-06-08 2015-12-23 南特生物科学公司 Triazine Derivatives and their Therapeutical Applications
EP2458995A1 (en) 2009-07-28 2012-06-06 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
EP2539348A4 (en) 2010-02-26 2013-07-24 Gary Igor Dmitrienko Cephalosporin derivatives useful as -lactamase inhibitors and compositions and methods of use thereof
CA2794334C (en) 2010-03-31 2018-06-12 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
US20110288063A1 (en) 2010-05-19 2011-11-24 Naeja Pharmaceutical Inc. Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors
US8822516B2 (en) 2010-06-10 2014-09-02 Technion Research & Development Foundation Limited Process for the preparation of iodides
ES2789177T3 (en) 2010-08-10 2020-10-26 Melinta Therapeutics Inc Cyclic boronic acid ester derivatives, process for their preparation and therapeutic uses thereof
DK2632927T3 (en) 2010-10-26 2016-04-11 Mars Inc Boronates AS ARGINSASEINHIBITORER
WO2012067664A1 (en) 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2508506A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Preparation of sitagliptin intermediates
CN102320960A (en) 2011-08-02 2012-01-18 安徽东健化工科技有限公司 Preparation method of 6-fluoro salicylic acid
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
WO2013056163A1 (en) 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
ES2699267T3 (en) 2011-12-22 2019-02-08 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteosome inhibitors
EP2802593A1 (en) 2012-01-09 2014-11-19 The University of Tromsoe Therapeutic boron-containing compounds
EP2615080A1 (en) 2012-01-12 2013-07-17 LEK Pharmaceuticals d.d. Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN105026407B (en) * 2012-12-07 2017-09-08 维纳拓尔斯制药公司 Beta lactamase restrainer
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EA201591003A1 (en) 2013-01-04 2015-12-30 Ремпекс Фармасьютикалз, Инк. DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX2015008627A (en) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Boronic acid derivatives and therapeutic uses thereof.
US9040504B2 (en) 2013-01-10 2015-05-26 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105283439B (en) 2013-03-15 2018-02-02 英特瑞克斯顿股份有限公司 The dibenzoylhydrazine of boracic
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
PL3140310T3 (en) 2014-05-05 2020-01-31 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
KR20170007448A (en) 2014-05-19 2017-01-18 렘펙스 파머수티클스 인코퍼레이티드 Boronic acid derivatives and therapeutic uses thereof
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
JP6622721B2 (en) 2014-06-11 2019-12-18 ベナトルクス ファーマシューティカルズ，インク． Beta-lactamase inhibitor
CN106536529B (en) 2014-07-01 2019-09-27 莱姆派克斯制药公司 Boronic acid derivatives and its therapeutical uses
WO2016065282A1 (en) 2014-10-24 2016-04-28 The Regents Of The University Of Michigan Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3285776B1 (en) 2015-04-24 2022-12-21 Melinta Therapeutics, Inc. Dosage regimen of vaborbactam and meropenem for treating bacterial infections in subjects with reduced renal function
KR102403296B1 (en) 2016-06-30 2022-05-27 큐펙스 바이오파마 인코포레이티드 Boronic acid derivatives and therapeutic uses thereof
MX2020003495A (en) 2017-10-11 2020-09-18 Qpex Biopharma Inc Boronic acid derivatives and synthesis thereof.

Also Published As

Publication number Publication date
EP3478693A4 (en) 2020-02-19
EP3478693A1 (en) 2019-05-08
PH12018502747A1 (en) 2019-12-11
KR102403296B1 (en) 2022-05-27
ES2894251T3 (en) 2022-02-14
US20220056055A1 (en) 2022-02-24
UA124464C2 (en) 2021-09-22
PL3478693T3 (en) 2021-12-13
US20200181177A1 (en) 2020-06-11
SG11201811549UA (en) 2019-01-30
KR20190025953A (en) 2019-03-12
MX2018015892A (en) 2019-06-20
ZA201808327B (en) 2022-04-28
BR112018077015A2 (en) 2019-04-02
AU2017290060A1 (en) 2018-12-20
US10570159B2 (en) 2020-02-25
US11180512B2 (en) 2021-11-23
CN109415386A (en) 2019-03-01
US10294249B2 (en) 2019-05-21
RU2018143900A3 (en) 2020-09-29
PT3478693T (en) 2021-10-25
RU2018143900A (en) 2020-07-30
US20190233443A1 (en) 2019-08-01
IL263450A (en) 2019-01-31
CA3026582A1 (en) 2018-01-04
CL2018003681A1 (en) 2019-04-26
DK3478693T3 (en) 2021-09-20
SA518400742B1 (en) 2023-02-28
AU2017290060B2 (en) 2021-07-22
IL263450B (en) 2022-01-01
WO2018005662A1 (en) 2018-01-04
CN109415386B (en) 2022-04-19
CO2018013978A2 (en) 2019-02-08
JP2019527196A (en) 2019-09-26
BR112018077015B1 (en) 2022-05-03
EP3478693B1 (en) 2021-07-21
JP7060245B2 (en) 2022-04-26
US20180002351A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12017501191A1 (en) Quinazoline derivatives used to treat hiv
MX2019005379A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof.
PH12017501921A1 (en) Novel compounds
EA201692301A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
EA201691988A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
EA201591003A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
EA201790389A1 (en) PYRROPYRIMIDINE COMPOUNDS USED AS AN AGLIST TLR7
EA201891063A1 (en) DERIVATIVES OF DIHYDROIMIDAZOPIRAZINONE APPLICABLE IN THE TREATMENT OF CANCER
MX2017008518A (en) Isoquinoline compounds for the treatment of hiv.
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
MX2017014035A (en) Solid forms.
MX2016015565A (en) Certain protein kinase inhibitors.
PH12016501462A1 (en) Neprilysin inhibitors
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
TW201613864A (en) Novel compounds
EA201790949A1 (en) SUBSTITUTED 2,4-DIAMINOCHINOLINES AS NEW ANTI-CANCER FACILITIES
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
EA201890906A1 (en) DERIVATIVES OF CHINOXALINE AND PYRIDOPYRASINE AS PI3Kβ INHIBITORS
MX2017008074A (en) IMIDAZOPYRIDAZINE DERIVATIVES AS PI3Kß INHIBITORS.
MX2017008076A (en) Heterocyclyl linked imidazopyridazine derivatives as pi3kbeta inhibitors.
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
MX2017013103A (en) Methods for the treatment of cardiovascular disorders.
EA201891136A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING AS A ACTIVE INGREDIENT DERIVATIVE 7-AZAINDOLIN-2-SHE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT